Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo, UMN Pharma Sign Collaborative Research Deal for Norovirus Vaccine
February 18, 2014
- Blopress AGs Approved, Yet Blurry Prospect for Their June Listing
February 17, 2014
- Kissei, Alteogen Agree on Business Collaboration for Biosimilar Development
February 17, 2014
- LEO Pharma’s New Japan Head Takes Office
February 17, 2014
- Once-Monthly Injectable Abilify Maintena Approved in Canada: Otsuka, Lundbeck
February 17, 2014
- New Suspicion Hints Close Link between Novartis, SIGN Initiator Group
February 17, 2014
- Nichi-Iko on Tap to Enter US Market, Remicade Biosimilar Debut Eyed around 2018
February 14, 2014
- Qol to Introduce Bidding System for Drug Purchasing Aimed at Avoiding Reduction in Basic Dispensing Fees Received
February 14, 2014
- Ex-Bellsystem24 Exec Deguchi to Spearhead AbbVie Japan
February 13, 2014
- Kyowa Kirin Temporarily Drops Untreated ATL Indication for Poteligeo
February 13, 2014
- Kaken Licenses Container Technology for Efinaconazole to Valeant
February 13, 2014
- AnGes Sales Up 10.5% but Logs 1,409 Million Yen Net Loss in 2013
February 12, 2014
- Ethical Drug Sales Up 4.7% in December: Crecon Report
February 12, 2014
- Asahi Kasei Pharma Completes 2nd Manufacturing Facility at Nagoya Pharmaceuticals Plant
February 12, 2014
- Novartis Appoints Former Tokyo High Court Judge to Head Independent Commission to Investigate Scandal Over SIGN Study
February 10, 2014
- Transdermal Parkinson’s Disease Treatment Ropinirole Shows Significant Difference in PII Study: Hisamitsu
February 10, 2014
- Mitsubishi Chemical to Set Up New Healthcare Firm
February 7, 2014
- MTPC Appoints Development Division Manager as New Representative Director
February 7, 2014
- Takeda CFO Says Midterm Strategy Not Affected by Halt of TAK-875 Trials
February 7, 2014
- Astellas to Bring Global Development, Regulatory Affairs Functions Under Control of Chief Medical Officer
February 7, 2014
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…